Compare AbbVie Inc (ABBV) vs Old Dominion Freight Line Inc (ODFL) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

ODFL stock trades at $216.36, up 2.34% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $1.68 versus $1.54 expected, driven by yield improvements and cost discipline. The company maintains robust profitability with a net income margin of 19.44% and ROE of 24.82%, though revenue has declined from $6.3B in 2022 to $5.5B in 2025. Analyst consensus price target is $239.85, suggesting upside potential.

Outlook is mixed: earnings momentum and a solid balance sheet support growth, but high valuation ratios (P/E of 41.6) and freight volume pressures pose risks. Investors should weigh the premium pricing against operational efficiency gains and market recovery prospects.